NCT03700788

Brief Summary

This is a Pilot Phase III single-blind randomized controlled clinical trial in patients, aged 18 years and older, presenting with symptoms of apical periodontitis. The overall goal is to assess whether 2% Chlorhexidine (CHX) is superior to Calcium Hydroxide in reducing interappointment pain.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started May 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 5, 2018

Completed
4 months until next milestone

First Posted

Study publicly available on registry

October 9, 2018

Completed
4.6 years until next milestone

Study Start

First participant enrolled

May 30, 2023

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2025

Completed
Last Updated

March 8, 2023

Status Verified

March 1, 2023

Enrollment Period

2.1 years

First QC Date

June 5, 2018

Last Update Submit

March 6, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • 2% Chlorhexidine (CHX) vs CaOH2 (CH) Calcium Hydroxide Paste as an Intracanal Medicament.

    The endpoint for the proposed study will be self-reported pain post-bite test, as recorded on the visual analog scale (VAS) 7 (+/- 2) days post treatment. We will be using the Visual Analog Scale (range 1-100) and plan to analyze this as a continuous variable to maintain maximum statistical power.

    7 days (+/- 2 days) post treatment

Secondary Outcomes (1)

  • Is 2% Chlorhexidine (CHX) better than Calcium Hydroxide in terms of producing fewer adverse events?

    7 days (+/- 2 days) post treatment

Study Arms (2)

Clorhexidine

EXPERIMENTAL

2% Chlorhexidine

Drug: Chlorhexidine

Calcium Hydroxide

ACTIVE COMPARATOR

Calcium Hydroxide

Drug: Calcium Hydroxide

Interventions

2% Chorhexidine (intracranial; remains in canal until removal at next visit)

Clorhexidine

Calcium Hydroxide (intracranial; remains in canal until removal at next visit)

Calcium Hydroxide

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years and older
  • symptomatic apical periodontitis (positive to the bite test)
  • restorable tooth
  • requires root canal therapy
  • able to undergo informed consent process
  • must be English or Spanish speaker

You may not qualify if:

  • Cracked tooth
  • non-restorable tooth
  • no pain medication or antibiotic taken in the past 3 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Herman Ostrow USC School of Dentistry

Los Angeles, California, 90089, United States

Location

MeSH Terms

Conditions

Periapical Periodontitis

Interventions

ChlorhexidineCalcium Hydroxide

Condition Hierarchy (Ancestors)

Periapical DiseasesJaw DiseasesStomatognathic DiseasesPeriodontal DiseasesMouth DiseasesPeriodontitis

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic ChemicalsHydroxidesAlkaliesInorganic ChemicalsCalcium CompoundsAnionsIonsElectrolytes

Study Officials

  • Rafael Roges, D.D.S.

    Director, Advanced Endodontics

    STUDY DIRECTOR

Central Study Contacts

Ramon Roges, D.D.S.

CONTACT

C L Fath, D.D.S.

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Participant will be unaware as to which medication is used in the treatment procedure and will also be self-reporting outcomes.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor, Director

Study Record Dates

First Submitted

June 5, 2018

First Posted

October 9, 2018

Study Start

May 30, 2023

Primary Completion

June 30, 2025

Study Completion

August 31, 2025

Last Updated

March 8, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations